Abstract
Alzheimers disease is a devastating degenerative disorder for which there is no cure or effective treatment. Although the etiology of Alzheimers disease is not fully understood, compelling evidence indicates that deposition of aggregates composed by a misfolded form of the amyloid beta peptide (Aβ) is the central event in the disease pathogenesis. Therefore, an attractive therapeutic strategy is to prevent or reverse Aβ misfolding and aggregation. Diverse strategies have been described to identify inhibitors of this process, including screening of libraries of small molecules chemical compounds, rational design of synthetic peptides, assessment of natural Aβ-binding proteins and stimulation of the immune system by vaccination. In this article we describe these different approaches, their principles and their potential strengths and weaknesses. Overall the available data suggest that the development of drugs to interfere with Aβ misfolding and aggregation is a feasible target that hold great promise for the treatment of Alzheimers disease.
Keywords: Aggregation inhibitors, β-sheet breakers, amyloid, Alzheimer's disease
Current Topics in Medicinal Chemistry
Title: Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Volume: 7 Issue: 1
Author(s): L. D. Estrada and C. Soto
Affiliation:
Keywords: Aggregation inhibitors, β-sheet breakers, amyloid, Alzheimer's disease
Abstract: Alzheimers disease is a devastating degenerative disorder for which there is no cure or effective treatment. Although the etiology of Alzheimers disease is not fully understood, compelling evidence indicates that deposition of aggregates composed by a misfolded form of the amyloid beta peptide (Aβ) is the central event in the disease pathogenesis. Therefore, an attractive therapeutic strategy is to prevent or reverse Aβ misfolding and aggregation. Diverse strategies have been described to identify inhibitors of this process, including screening of libraries of small molecules chemical compounds, rational design of synthetic peptides, assessment of natural Aβ-binding proteins and stimulation of the immune system by vaccination. In this article we describe these different approaches, their principles and their potential strengths and weaknesses. Overall the available data suggest that the development of drugs to interfere with Aβ misfolding and aggregation is a feasible target that hold great promise for the treatment of Alzheimers disease.
Export Options
About this article
Cite this article as:
Estrada D. L. and Soto C., Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment, Current Topics in Medicinal Chemistry 2007; 7 (1) . https://dx.doi.org/10.2174/156802607779318262
DOI https://dx.doi.org/10.2174/156802607779318262 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cells and Cardiac Disease: Where are We Going?
Current Stem Cell Research & Therapy Immunomodulatory Activity of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Performance Improvement of Gene Selection Methods using Outlier Modification Rule
Current Bioinformatics Targeting Calcium and the Mitochondria in Prevention of Pathology in the Heart
Current Drug Targets Hyperhomocysteinemia and Sudden Cardiac Death: Potential Arrhythmogenic Mechanisms
Current Vascular Pharmacology Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Lipid Rafts and Redox Regulation of Cellular Signaling in Cholesterol Induced Atherosclerosis
Current Cardiology Reviews The Cardiac Microvasculature in Hypertension, Cardiac Hypertrophy and Diastolic Heart Failure
Current Vascular Pharmacology Cardioprotective Potential of Iron Chelators and Prochelators
Current Medicinal Chemistry Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Mitochondrial Disorders in Adults
Current Molecular Medicine Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Chymase in Vascular Remodeling and Tissue Fibrosis
Current Hypertension Reviews Energetic Metabolic Roles in Pulmonary Arterial Hypertension and Right Ventricular Remodeling
Current Pharmaceutical Design Therapeutic Applications of Calcium Metabolism Modulation in Heart Disease
Medicinal Chemistry High Sensitivity Troponin in Cardiovascular Disease. Is There More Than a Marker of Myocardial Death?
Current Topics in Medicinal Chemistry Human Urotensin II and Metabolic Syndrome
Vascular Disease Prevention (Discontinued) Sepsis-induced Cardiomyopathy
Current Cardiology Reviews Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons
Current Cardiology Reviews